XML 39 R32.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration and License Agreements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2016
Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Potential Additional Cash Receipt   $ 65,000   $ 65,000      
Research and development   8,090 $ 13,126 18,407 $ 24,838    
Collaboration revenue   1,610 $ 2,165 3,612 $ 4,129    
Deferred revenue   1,298   1,298     $ 4,911
Kaken License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront payments $ 15,000     15,000      
HMNC Agreement [Member]              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Payment of License       0      
Eli Lilly And Company [Member] | Lilly License Agreement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Potential Additional Payment   $ 23,000   23,000      
Research and development arrangement, costs incurred       $ 0      
Research and development           $ 800